Related Experiment Video
Updated: Feb 13, 2026

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
HER2 Deregulation in Lung Cancer: Right Time to Adopt an Orphan?
Federico Cappuzzo1, Lorenza Landi2
1Medical Oncology Department, AUSL della Romagna, Ravenna, Italy. federico.cappuzzo@auslromagna.it.
Abstract:
HER2-deregulated non-small cell lung cancer is an orphan of any specific therapy, probably because of lack of both accurate patient selection and effective drugs. Recent evidence suggests that osimertinib could be effective in HER2-amplified or mutated lung cancer as a single agent or in combination. Clin Cancer Res; 24(11); 2470-2. ©2018 AACRSee related article by Liu et al., p. 2594.
Insights
HER2-deregulated non-small cell lung cancer lacks targeted therapies. Osimertinib shows promise as a potential treatment for HER2-amplified or mutated lung cancer, alone or in combination.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- HER2-deregulated non-small cell lung cancer (NSCLC) currently lacks specific therapies due to challenges in patient selection and drug development.
- HER2 alterations are found in a subset of NSCLC patients, representing an unmet therapeutic need.
Purpose of the Study:
- To explore the potential efficacy of osimertinib in treating HER2-altered NSCLC.
- To evaluate osimertinib as a single agent or in combination therapy for HER2-driven lung cancer.
Main Methods:
- Review of recent evidence and clinical data regarding osimertinib activity in HER2-altered NSCLC.
- Analysis of potential patient selection strategies for HER2-targeted therapies.
Main Results:
- Emerging evidence suggests osimertinib may be effective in HER2-amplified or mutated NSCLC.
- Osimertinib demonstrates potential as both a monotherapy and a combination treatment option.
Conclusions:
- Osimertinib represents a promising therapeutic avenue for patients with HER2-deregulated NSCLC.
- Further research is warranted to optimize patient selection and treatment strategies involving osimertinib for HER2-altered lung cancer.
Related Concept Videos
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Lung Capacity
Pleura of the Lungs
Gross Anatomy of the Lungs
Cancer
Mixing Time

